* Phathom Pharmaceuticals Inc reported a quarterly adjusted loss of $1.32 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of seven analysts for the quarter was for a loss of $1.49 per share. Wall Street expected results to range from $-1.74 to $-1.22 per share.
* Revenue was $16.35 million; analysts expected $12.61 million.
* Phathom Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.32.
* The company reported a quarterly loss of $85.58 million.
* Phathom Pharmaceuticals Inc shares had fallen by 0.4% this quarter and gained 97.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 3.1% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is 24.00 This summary was machine generated from LSEG data November 7 at 03:10 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.49
Jun. 30 2024 -1.38
Mar. 31 2024 -1.31
Dec. 31 2023 -1.08 -1.39 Missed
Comments